Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab

Nephrology

Volumn 22, Issue , 2017, Pages 18-22

  Chua, Justin ^a   Paizis, Kathy ^a   He, Simon Z ^a   Mount, Peter ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

Acute kidney injury; atypical haemolytic uraemic syndrome; eculizumab; haemolysis; peri partum; pregnancy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; BILIRUBIN; CREATININE; ECULIZUMAB; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; UREA; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTERY PERFORATION; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN DISEASE; CASE REPORT; CESAREAN SECTION; COLOSTOMY; CONVALESCENCE; DIALYSIS; DISEASE SEVERITY; ECHOGRAPHY; ELECTROENCEPHALOGRAM; ENZYME ACTIVITY; FATTY LIVER; FEMALE; FETUS DEATH; FETUS ECHOGRAPHY; FETUS MOVEMENT; FEVER; HEMOFILTRATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; INTESTINE ISCHEMIA; INTESTINE RESECTION; INTUBATION; ISCHEMIC COLITIS; KIDNEY FUNCTION; LIVER DISEASE; LUNG EMBOLISM; MALNUTRITION; MENTAL DETERIORATION; MYOPATHY; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PLASMA EXCHANGE; PLEURA EFFUSION; POLYURIA; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PROTEINURIA; PUERPERIUM; REMISSION; RETICULOCYTE COUNT; REVIEW; SEPTIC SHOCK; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VAGINA BLEEDING; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLICATION; PREGNANCY; PUERPERAL DISORDERS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; FETAL DEATH; HUMANS; PREGNANCY; PUERPERAL DISORDERS;

EID: 85011878249     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12935     Document Type: Review

References (13)

1. Noris M, Remuzzi G. Atypical hemolytic–uremic syndrome. N. Engl. J. Med. 2009; 361 (17): 1676–1687.
2. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 2010; 21 (5): 859–867.
3. Saad AF, Roman J, Wyble A, Pacheco LD. Pregnancy-associated atypical hemolytic-uremic syndrome. Am. J. Perinatol. Rep. 2016; 6 (01): e125–e128.
4. Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: A single-arm, open-label trial. Am. J. Kidney Dis. 2016.
5. Machado S, Figueiredo N, Borges A, et al. Acute kidney injury in pregnancy: a clinical challenge. 2012.
6. Cataland SR, Yang S, Wu HM. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br. J. Haematol. 2012; 157 (4): 501–503.
7. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins. 2012; 4 (11): 1261–1287.
8. Caprioli J, Noris M, Brioschi S et al. International registry of recurrent and familial HUS/TTP. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108 (4): 1267–1279.
9. Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br. Med. Bull. 2006; 77 (1): 5–22.
10. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 2011; 6 (1): 1.
11. Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J. Nephrol. 2016: 1–8.
12. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015; 87 (5): 1061–1073.
13. Ardissino G, Testa S, Possenti I et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am. J. Kidney Dis. 2014; 64 (4): 633–637.